{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:20:08Z","timestamp":1790256008085,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science and Technology of China","award":["2017YFC1311100"],"award-info":[{"award-number":["2017YFC1311100"]}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"crossref","award":["Z161100000516001"],"award-info":[{"award-number":["Z161100000516001"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"crossref","award":["Z161100002616021"],"award-info":[{"award-number":["Z161100002616021"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objectives of this study were to investigate whether the plasma levels of oligomeric amyloid-\u03b2 (OA\u03b2) were affected in Alzheimer\u2019s disease (AD) and to examine the associations (or possible correlations) between plasma OA\u03b2 levels and memory performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Thirty subjects with AD and 28 cognitively normal controls were recruited in the study. The multimer detection system (MDS) was used to measure the levels of OA\u03b2 in the plasma. In addition to assessing the general cognitive function with the Mini-Mental State Examination (MMSE), Cognitive Abilities Screening Instrument (CASI), and Alzheimer\u2019s Disease Assessment Scale\u2013cognitive portion (ADAS-Cog), the common objects memory test (COMT) was used to examine the episodic memory performance. Pearson\u2019s and partial correlation analyses were conducted to explore the associations between cognitive performance and OA\u03b2 levels in the plasma. A receiving operating curve (ROC) analysis was used to discriminate between the AD and control groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The plasma OA\u03b2 levels in the AD group were significantly higher than those in the control group [1.88 (0.38) ng\/ml vs 1.20 (0.40) ng\/ml,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001]. The elevated levels of plasma OA\u03b2 showed a strong correlation with cognitive performance in patients with AD, including an inverse correlation with scores on the MMSE (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.43,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), CASI (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.56,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), and the immediate recall (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.45,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), 5-min delayed recall (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.56,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), and 30-min delayed recall (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.71,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) tests of the COMT, and a positive correlation with the ADAS-Cog scores (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.59,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The EDTA plasma A\u03b2 oligomer optical density (OD) value measured using the MDS could discriminate between the AD and control groups with an area under the curve (AUC) of 0.89. The optimal sensitivity and specificity were 82.1% and 90.0%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The elevated levels of OA\u03b2 in the plasma distinguished the AD and control groups and were associated with the severity of symptoms, especially memory performance, in patients with AD. Our results suggested that plasma OA\u03b2 could potentially be a simple and non-invasive blood-based biomarker for AD diagnosis. Furthermore, longitudinal studies are warranted to explore the application of plasma OA\u03b2 levels as a valid diagnostic biomarker in patients with AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-019-0535-7","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T13:50:04Z","timestamp":1572011404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Association between increased levels of amyloid-\u03b2 oligomers in plasma and episodic memory loss in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"11","author":[{"given":"Xue","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungmin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SangYun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Soo A.","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3213-6493","authenticated-orcid":false,"given":"Huali","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"issue":"5580","key":"535_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136. \n                    https:\/\/doi.org\/10.1126\/science.1072994\n                    \n                  .","journal-title":"Science"},{"issue":"4","key":"535_CR2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","volume":"27","author":"PN Lacor","year":"2007","unstructured":"Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. A\u03b2 oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer\u2019s disease. J Neurosci. 2007;27(4):796\u2013807. \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.3501-06.2007\n                    \n                  .","journal-title":"J Neurosci"},{"issue":"8","key":"535_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-\u03b2 protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837\u201342. \n                    https:\/\/doi.org\/10.1038\/nm1782\n                    \n                  .","journal-title":"Nat Med"},{"key":"535_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neurobiolaging.2018.06.025","volume":"71","author":"W Gulisano","year":"2018","unstructured":"Gulisano W, Melone M, Li Puma DD, Tropea MR, Palmeri A, Arancio O, et al. The effect of amyloid-\u03b2 peptide on synaptic plasticity and memory is influenced by different isoforms, concentrations, and aggregation status. Neurobiol Aging. 2018;71:51\u201360. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.06.025\n                    \n                  .","journal-title":"Neurobiol Aging"},{"issue":"4","key":"535_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3233\/JAD-171110","volume":"62","author":"TT Hou","year":"2018","unstructured":"Hou TT, Yang HY, Wang W, Wu QQ, Tian YR, Jia JP. Sulforaphane inhibits the generation of amyloid-\u03b2 oligomer and promotes spatial learning and memory in Alzheimer\u2019s disease (PS1V97L) transgenic mice. J Alzheimers Dis. 2018;62(4):1803\u201313. \n                    https:\/\/doi.org\/10.3233\/JAD-171110\n                    \n                  .","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"535_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","volume":"129","author":"KL Viola","year":"2015","unstructured":"Viola KL, Klein WL. Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129(2):183\u2013206. \n                    https:\/\/doi.org\/10.1007\/s00401-015-1386-3\n                    \n                  .","journal-title":"Acta Neuropathol"},{"issue":"2","key":"535_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00702-017-1820-x","volume":"125","author":"B Mroczko","year":"2018","unstructured":"Mroczko B, Groblewska M, Litman-Zawadzka A, Kornhuber J, Lewczuk P. Amyloid \u03b2 oligomers (A\u03b2Os) in Alzheimer\u2019s disease. J Neural Transm. 2018;125(2):177\u201391. \n                    https:\/\/doi.org\/10.1007\/s00702-017-1820-x\n                    \n                  .","journal-title":"J Neural Transm"},{"issue":"8","key":"535_CR8","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1523\/jneurosci.1675-13.2014","volume":"34","author":"MJ Savage","year":"2014","unstructured":"Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, et al. A sensitive A\u03b2 oligomer assay discriminates Alzheimer\u2019s and aged control cerebrospinal fluid. J Neurosci. 2014;34(8):2884\u201397. \n                    https:\/\/doi.org\/10.1523\/jneurosci.1675-13.2014\n                    \n                  .","journal-title":"J Neurosci"},{"issue":"1","key":"535_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JAD-2012-111361","volume":"29","author":"AN Santos","year":"2012","unstructured":"Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, et al. Amyloid-\u03b2 oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer\u2019s disease. J Alzheimers Dis. 2012;29(1):171\u20136. \n                    https:\/\/doi.org\/10.3233\/JAD-2012-111361\n                    \n                  .","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"535_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3233\/jad-122047","volume":"34","author":"L Wang-Dietrich","year":"2013","unstructured":"Wang-Dietrich L, Funke SA, Kuhbach K, Wang K, Besmehn A, Willbold S, et al. The amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer\u2019s disease. J Alzheimers Dis. 2013;34(4):985\u201394. \n                    https:\/\/doi.org\/10.3233\/jad-122047\n                    \n                  .","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"535_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/jmri.20669","volume":"24","author":"H Wang","year":"2006","unstructured":"Wang H, Golob EJ, Su MY. Vascular volume and blood-brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls. J Magn Reson Imaging. 2006;24(3):695\u2013700. \n                    https:\/\/doi.org\/10.1002\/jmri.20669\n                    \n                  .","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"535_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133\u201350. \n                    https:\/\/doi.org\/10.1038\/nrneurol.2017.188\n                    \n                  .","journal-title":"Nat Rev Neurol"},{"key":"535_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.neurobiolaging.2016.03.034","volume":"52","author":"C Cerami","year":"2017","unstructured":"Cerami C, Dubois B, Boccardi M, Monsch AU, Demonet JF, Cappa SF. Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:153\u201366. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.03.034\n                    \n                  .","journal-title":"Neurobiol Aging"},{"issue":"8","key":"535_CR14","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734\u201346. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(07)70178-3\n                    \n                  .","journal-title":"Lancet Neurol"},{"issue":"8","key":"535_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jalz.2016.12.014","volume":"13","author":"M Teichmann","year":"2017","unstructured":"Teichmann M, Epelbaum S, Samri D, Levy Nogueira M, Michon A, Hampel H, et al. Free and cued selective reminding test\u2013accuracy for the differential diagnosis of Alzheimer\u2019s and neurodegenerative diseases: a large-scale biomarker-characterized monocenter cohort study (ClinAD). Alzheimers Dement. 2017;13(8):913\u201323. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2016.12.014\n                    \n                  .","journal-title":"Alzheimers Dement"},{"issue":"10","key":"535_CR16","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1212\/WNL.0000000000001774","volume":"85","author":"KB Rajan","year":"2015","unstructured":"Rajan KB, Wilson RS, Weuve J, Barnes LL, Evans DA. Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology. 2015;85(10):898\u2013904. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000001774\n                    \n                  .","journal-title":"Neurology."},{"issue":"2","key":"535_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/archneurol.2008.565","volume":"66","author":"W Xia","year":"2009","unstructured":"Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, et al. A specific enzyme-linked immunosorbent assay for measuring \u03b2-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009;66(2):190\u20139. \n                    https:\/\/doi.org\/10.1001\/archneurol.2008.565\n                    \n                  .","journal-title":"Arch Neurol"},{"issue":"4","key":"535_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.bbrc.2012.06.017","volume":"423","author":"L Zhou","year":"2012","unstructured":"Zhou L, Chan KH, Chu LW, Kwan JSC, Song YQ, Chen LH, et al. Plasma amyloid-\u03b2 oligomers level is a biomarker for Alzheimer\u2019s disease diagnosis. Biochem Biophys Res Commun. 2012;423(4):697\u2013702. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2012.06.017\n                    \n                  .","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"535_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-017-0324-0","volume":"9","author":"MJ Wang","year":"2017","unstructured":"Wang MJ, Yi S, Han JY, Park SY, Jang JW, Chun IK, et al. Oligomeric forms of amyloid-\u03b2 protein in plasma as a potential blood-based biomarker for Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9(1):1\u201310. \n                    https:\/\/doi.org\/10.1186\/s13195-017-0324-0\n                    \n                  .","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"535_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.12779\/dnd.2018.17.2.41","volume":"17","author":"Y Yang","year":"2018","unstructured":"Yang Y, Van GV, An SSA, Kim S. Plasma oligomeric beta amyloid in Alzheimer\u2019s disease with history of agent orange exposure. Dement Neurocogn Disord. 2018;17(2):41\u20139. \n                    https:\/\/doi.org\/10.12779\/dnd.2018.17.2.41\n                    \n                  .","journal-title":"Dement Neurocogn Disord"},{"key":"535_CR21","doi-asserted-by":"publisher","unstructured":"An SSA, Lee B, Yu JS, Lim K, Kim GJ, Lee R, et al. Dynamic changes of oligomeric amyloid \u03b2 levels in plasma induced by spiked synthetic A\u03b242. Alzheimers Res Ther. 2017:1\u201310. \n                    https:\/\/doi.org\/10.1186\/s13195-017-0310-6\n                    \n                  .","DOI":"10.1186\/s13195-017-0310-6"},{"issue":"1","key":"535_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-019-0499-7","volume":"11","author":"YC Youn","year":"2019","unstructured":"Youn YC, Kang S, Suh J, Park YH, Kang MJ, Pyun J-M, et al. Blood amyloid-\u03b2 oligomerization associated with neurodegeneration of Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11(1):40\u20137. \n                    https:\/\/doi.org\/10.1186\/s13195-019-0499-7\n                    \n                  .","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"535_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3233\/JAD-142556","volume":"45","author":"X Wang","year":"2015","unstructured":"Wang X, Wang J, He Y, Li H, Wang H. Apolipoprotein E\u03b54 modulates cognitive profiles, hippocampal volume, and resting-state functional connectivity in Alzheimer\u2019s disease. J Alzheimers Dis Jad. 2015;45(3):781\u201395. \n                    https:\/\/doi.org\/10.3233\/JAD-142556\n                    \n                  .","journal-title":"J Alzheimers Dis Jad"},{"issue":"1","key":"535_CR24","first-page":"13","volume":"2","author":"G Li","year":"1988","unstructured":"Li G, Shen Y, Chen C, Li S, Zhao Y, Liu M, et al. Study on the brief testing for dementia: testing MMSE among urban elderly. Chin Ment Health J. 1988;2(1):13\u20138.","journal-title":"Chin Ment Health J"},{"issue":"1","key":"535_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1017\/S1041610294001602","volume":"6","author":"EL Teng","year":"1994","unstructured":"Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, et al. The cognitive abilities screening instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr. 1994;6(1):45\u201358. \n                    https:\/\/doi.org\/10.1017\/S1041610294001602\n                    \n                  .","journal-title":"Int Psychogeriatr"},{"key":"535_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.wad.0000137521.61487.68","volume":"18","author":"H Wang","year":"2004","unstructured":"Wang H, Yu X, Li S, Chen Y, Li H, He J. The cognitive subscale of Alzheimer\u2019s disease assessment scale, Chinese version in staging of Alzheimer disease. Alzheimer Dis Assoc Disord. 2004;18:231\u20135.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"535_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1017\/S1355617710000160","volume":"16","author":"D Kempler","year":"2010","unstructured":"Kempler D, Teng EL, Taussig M, Dick MB. The common objects memory test (COMT): a simple test with cross-cultural applicability. J Int Neuropsychol Soc. 2010;16(3):537\u201345. \n                    https:\/\/doi.org\/10.1017\/S1355617710000160\n                    \n                  .","journal-title":"J Int Neuropsychol Soc"},{"issue":"45","key":"535_CR28","doi-asserted-by":"publisher","first-page":"10191","DOI":"10.1523\/JNEUROSCI.3432-04.2004","volume":"24","author":"P. N. Lacor","year":"2004","unstructured":"Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al. Synaptic targeting by Alzheimer\u2019s-related amyloid \u03b2 oligomers. 2004;24(45):10191\u2013200. \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.3432-04.2004\n                    \n                  .","journal-title":"Journal of Neuroscience"},{"issue":"1","key":"535_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/jad-142136","volume":"45","author":"W Jongbloed","year":"2015","unstructured":"Jongbloed W, Bruggink KA, Kester MI, Visser PJ, Scheltens P, Blankenstein MA, et al. Amyloid-beta oligomers relate to cognitive decline in Alzheimer\u2019s disease. J Alzheimers Dis. 2015;45(1):35\u201343. \n                    https:\/\/doi.org\/10.3233\/jad-142136\n                    \n                  .","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"535_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nbd.2009.05.024","volume":"35","author":"JL Tomic","year":"2009","unstructured":"Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer\u2019s disease brain and correlate with cognitive dysfunction. Neurobiol Dis. 2009;35(3):352\u20138. \n                    https:\/\/doi.org\/10.1016\/j.nbd.2009.05.024\n                    \n                  .","journal-title":"Neurobiol Dis"},{"key":"535_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neulet.2013.06.029","volume":"551","author":"T Kasai","year":"2013","unstructured":"Kasai T, Tokuda T, Taylor M, Kondo M, Mann DM, Foulds PG, et al. Correlation of Abeta oligomer levels in matched cerebrospinal fluid and serum samples. Neurosci Lett. 2013;551:17\u201322. \n                    https:\/\/doi.org\/10.1016\/j.neulet.2013.06.029\n                    \n                  .","journal-title":"Neurosci Lett"},{"issue":"8","key":"535_CR32","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1096\/fj.09-150359","volume":"24","author":"H Fukumoto","year":"2010","unstructured":"Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, et al. High-molecular-weight \u03b2-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 2010;24(8):2716\u201326. \n                    https:\/\/doi.org\/10.1096\/fj.09-150359\n                    \n                  .","journal-title":"FASEB J"},{"issue":"8","key":"535_CR33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, et al. Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol. 2017;16(8):661\u201376. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(17)30159-X\n                    \n                  .","journal-title":"Lancet Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0535-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0535-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0535-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T19:16:18Z","timestamp":1603480578000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0535-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0535-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"1 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review board of Peking University Institute of Mental Health (Sixth Hospital) approved the study. Written informed consent was obtained from each participant. The patient and his\/her legal guardian both provided written consent for the patient to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Sungmin Kang is the founder of PeopleBio, Inc. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}